Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma.
Hamid EhsanAhsan WahabZunairah ShahMuhammad Khawar SanaAdeel MasoodAbdul RafaeHamza HashmiPublished in: Journal of hematology (2021)
Biomarker-driven targeted therapies have been an area of exploration for innovative therapeutic options in oncology. B-cell lymphoma-2 (BCL-2) protein is an anti-apoptotic protein expressed on the clonal plasma cells in patients with multiple myeloma (MM). MM subsets with t (11;14) have overexpression of BCL-2 and can benefit from venetoclax (VEN) when used either alone or in combination with other chemotherapeutic agents with an overall response rate (ORR) ranging from 40% to 100%. The most commonly reported grade ≥ 3 adverse effects include cytopenias and gastrointestinal side effects. This review highlights the meaningful efficacy and tolerable safety of VEN monotherapy and its combination regimens in the treatment of relapsed refractory MM.
Keyphrases
- multiple myeloma
- diffuse large b cell lymphoma
- acute lymphoblastic leukemia
- acute myeloid leukemia
- cell death
- combination therapy
- induced apoptosis
- palliative care
- protein protein
- transcription factor
- amino acid
- cell cycle arrest
- small molecule
- binding protein
- chronic lymphocytic leukemia
- open label
- peripheral blood